Description
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
This trial is available at multiple Sutter Locations. Please contact one of the following about Study ECOG E4512
San Francisco: ClinicalResearch@sutterhealth.org
Palo Alto/Santa Cruz: Tanya Pozniansky pozniat@sutterhealth.org
East Bay: James Nasman NasmanJ@sutterhealth.org and Vivian Leong, RN Leongv@sutterhealth.org
Sacramento: Isabel Rodrigues-Fong Rodrigi@sutterhealth.org and Kirsten Babski babskik@sutterhealth.org
Modesto: Delia Massone MassonD@sutterhealth.org and Adrienne Palos PalosA@sutterhealth.org
Solano-Vallejo Cancer Center: Stephanie Gonzales gonzals@sutterhealth.org
View study details on ClinicalTrials.govPrincipal Investigator
Recruitment Status
Active, Recruiting
Start Date
February 01, 2019
Related Studies
The Impact of Smoking, Comorbidities, and Race/Ethnicity on COVID-19 Infection and Disease Severity
Investigator: Jiang Li, Ph.D., MPH